Metaplastic carcinoma of the breast (MpBC) is a very rare and aggressive type of breast cancer. Data focusing on MpBC are limited. The aim of this study was to describe the clinicopathological features of MpBC and evaluate the prognosis of patients with MpBC. Eligible articles about MpBC were identified by searching CASES SERIES gov and the MEDLINE bibliographic database for the period of 1 January 2010 to 1 June 2021 with the keywords metaplastic breast cancer, mammary gland cancer, neoplasm, tumor, and metaplastic carcinoma. In this study, we also report 46 cases of MpBC stemming from our hospital. Survival rates, clinical behavior, and pathological characteristics were analyzed. Data from 205 patients were included for analysis. The mean age at diagnosis was 55 (14.7) years. The TNM stage at diagnosis was mostly stage II (58.5%) and most tumors were triple negative. The median overall survival was 66 (12-118) months, and the median disease-free survival was 56.8 (11-102) months. Multivariate Cox regression analysis revealed that surgical treatment was associated with decreased risk of death (hazard ratio 0.11, 95% confidence interval 0.02-0.54, = 0.01) while advanced TNM stage was associated with increased risk of death (hazard ratio 1.5, 95% confidence interval 1.04-2.28, = 0.03). Our results revealed that surgical treatment and TNM stage were the only independent risk factors related to patients' overall survival.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204473 | PMC |
http://dx.doi.org/10.3390/medsci11020035 | DOI Listing |
Int J Surg Pathol
December 2024
Breast Department, KK Women's and Children's Hospital, Singapore.
Fibromatosis-like metaplastic carcinoma (FLMC) is a rare subtype of metaplastic carcinoma of the breast. Diagnosing this entity poses significant challenges, particularly in core biopsies due to limited sampling and overlap with benign spindle cell lesions such as nodular fasciitis and fibromatosis. We present an example of FLMC in an asymptomatic middle-aged woman.
View Article and Find Full Text PDFAm J Dermatopathol
November 2024
Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake City, UT.
Int J Surg Pathol
December 2024
James Homer Wright Pathology Laboratories, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Secretory carcinoma is a rare breast tumor driven by fusion. It has characteristic morphologic features and identification of these tumors is critical as these patients may benefit from TRK inhibitors. Morphologic shift upon treatment has not been reported in secretory carcinoma or other -driven tumors.
View Article and Find Full Text PDFCureus
November 2024
Internal Medicine, Weiss Memorial Hospital, Chicago, USA.
Esophageal cancer, particularly squamous cell carcinoma, poses significant diagnostic challenges due to its aggressive nature and similarity to metaplastic tissue. Accurate diagnosis often requires multiple biopsies and vigilant surveillance, especially in high-risk individuals with conditions such as gastroesophageal reflux disease (GERD) and a history of smoking. We present a 66-year-old female patient with a history of severe GERD and smoking, who underwent routine endoscopy revealing a gastric cardia nodule.
View Article and Find Full Text PDFHistopathology
December 2024
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Aims: Metaplastic breast carcinoma (MBC) is a heterogeneous group of invasive breast carcinoma with squamous, spindle cell, or mesenchymal elements. It may be monophasic or biphasic, and often coexists with invasive breast carcinoma of no special type (IBC-NST). Currently, there are no standardized guidelines for reporting MBC, and a diagnostic threshold for the metaplastic component is not established by the WHO classification.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!